The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize
Industry Leaders Back At The Wheel Are Driving Health Care Transformation
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
You may also be interested in...
Medtronic Looks Beyond The World Of Doctors And Devices In New Approach To Markets
Focus On Switzerland – Part 2. Health warning to global medtechs: the world’s largest medtech company is taking steps to strengthen key account management, retain its market share hold and set up new health care partnerships.
Pivotal Opportunity For UK Medtech Must Not Be Wasted
The UK continues to work on its new medtech regulatory system and market access processes for innovations, but all the planning and preparations will count for little if not accompanied by sound execution, warns Lincoln Tsang of law firm Ropes & Gray.
EU MDR Extended Transitions: Practical Advice From Commission
Concerns and uncertainties arising among manufacturers following the recent extension of the MDR's transition periods have been addressed in a question-and-answer document issued by the European Commission.